A vaccine trial targeting H5N1 bird flu has begun in humans. The virus has devastated bird populations globally but has not yet jumped between people. Researchers are developing this vaccine now, before H5N1 spreads to humans, as a precautionary measure against a potential pandemic.
H5N1 infects wild birds and poultry. Since 2020, the virus has killed millions of birds and infected some farm workers and other humans with direct animal exposure. Those human cases resulted in severe illness and death, but human-to-human transmission has remained rare.
Vaccine developers are racing ahead with clinical trials rather than waiting for widespread human infection. This strategy mirrors the pandemic preparedness approach taken with other dangerous pathogens. If H5N1 mutates or evolves to spread easily among people, an existing vaccine could help control outbreaks quickly.
The trial will test whether the vaccine triggers immune responses in healthy volunteers. Researchers will monitor safety and measure antibody production. Success could position this vaccine for rapid deployment if public health officials determine a broader rollout is necessary.
Experts emphasize that current bird flu risk to the general public remains low. However, continued surveillance of birds and animals is essential to catch any changes in the virus early.